1                               The beneficial antipruritic action of RMP may be explained, at least pa

2 Prostaglandin D(2) (PGD(2)) is known to have antipruritic activity by suppressing histamine release.

3  as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mous

4            Systemic muscimol or baclofen are antipruritic against both histamine-dependent and -indep

5 diates its anti-itch effects by boosting the antipruritic agent, PGD(2), by the activation of the p38

6 nd vanilloids may serve as targets for novel antipruritic agents.

7 nd-receptor systems into future therapies as antipruritics and/or analgesics in humans.

8 may provide a central therapeutic target for antipruritic drug development.

9 ify the critical brain centers mediating the antipruritic effect of butorphanol.

10  muscimol produced a significant synergistic antipruritic effect, with no sedation.

11 ith atopic dermatitis; however, the specific antipruritic mechanism of action remains unclear.

12                           We also tested the antipruritic properties of intraspinal transplantation o

13 counterstimuli relieve itch, resulting in an antipruritic state that persists for minutes to hours.

14 ritogenic pruritus), which may affect future antipruritic strategies.

15 talk between 5-HT1A and GRPR may be a useful antipruritic strategy.

16 ent potential targets for the development of antipruritic therapy.